AzTrials
AzTrials

Pulmonary HypertensionNCT02790918

Diagnosis of Pulmonary Hypertension Using Cardiac Magnetic Resonance Images

An observational study of Pulmonary Hypertension, run by National Heart Centre Singapore at 1 site in Singapore.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study, study team aim to i) evaluate the accuracy of 3D IVS curvedness for prediction of RV systolic pressure (RVSP), mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) with RHC; ii) evaluate the usefulness of 3D IVS curvedness for predicting the response to vasodilator challenge… Read more about this study

Who is it for?
Ages 16 to 99 yearsHealthy volunteers can take part
Conditions the study is for
Pulmonary Hypertension
What is being tested?
6MWT and Cardiovascular Magnetic Resonance Imaging (CMRI)
Type of treatment
Injection or infusion
How many people
60 participants
Where
1 siteSingapore
Study dates
May 2013to Oct 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: 30 diagnosed pulmonary hypertension patient will be recruited from primary care clinic and outpatient clinics from the National Heart Centre Singapore. 30 Healthy volunteer control.

Who may be able to join

  • Signed informed consent prior to initiation of any study mandated procedure
  • Age 16 years or more.
  • Patient with clinically suspected or known primary PH belonging to one of the Updated Dana Point Clinical Classification Groups (I-IV)
  • No known history of pulmonary hypertension

Who cannot join

  • Contraindication to MR examination:
  • Cardiac pacemaker
  • Brain aneurysm or clips
  • Electronic implants or prosthesis
  • Eye metal foreign body injury
  • Severe claustrophobia

Trial locations and contacts

1 site in 1 country.

Singapore1 site
  • National Heart Centre Singapore

    Singapore, 169609

Other trials in Singapore

About this study

Official title: Noninvasive Diagnosis of Pulmonary Hypertension Using Three-dimensional Interventricular Septal Curvedness From Cardiac Magnetic Resonance Images

In this study, study team aim to i) evaluate the accuracy of 3D IVS curvedness for prediction of RV systolic pressure (RVSP), mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) with RHC; ii) evaluate the usefulness of 3D IVS curvedness for predicting the response to vasodilator challenge with RHC, in patients clinically suspected or known to have primary PH.

Read the detailed description
  1. Pulmonary hypertension Pulmonary hypertension (PH) is manifested as an increase in mean pulmonary artery pressure (i.e., mPAP ≥ 25 mmHg) at rest on right heart catheterization (RHC) (Badesch 2009). It is a complex and multidisciplinary disorder causing restricted flow through the pulmonary arterial circulation due to increased pulmonary vascular resistance (PVR). It can be classified into five groups (Simonneau et al 2004): Group I - Idiopathic PAH, Familial PAH, and PAH associated with collagen vascular disease et al; Group II - PH with left heart disease; Group III - PH associated with lung diseases and/or hypoxemia; Group IV - PH due to chronic thrombotic and/or embolic disease; and Group V - miscellaneous causes of PH. The prognosis of PH is poor. The National Institutes of Health (NIH) Registry followed 194 patients with IPAH enrolled at 32 clinical centers from 1981 to 1985 (D'Alonzo et al 1991). The reported median survival rates of 68%, 48% and 34%. Similar results have been reported in Japan, India and Mexico.

Right heart catheterization (RHC) is the current reference standard for diagnosing PH (Galie et al 2009; McLaughlin et al 2009), according to ACCF/AHA expert consensus (McLaughlin et al 2009) and ESC/ERS guidelines (Galie et al 2009). Three hemodynamic measurements are essential from RHC: right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). Further, patients with PH undergo RHC to assess clinical response to vasodilator challenge in order to guide therapy. It helps identify patients with better prognosis and patients who could potentially benefit from treatment with calcium channel blockers. A positive acute response is defined as a reduction of pulmonary artery pressure ≥10mmHg and ≤40mmHg. Although RHC plays a pivotal role in PH diagnosis, it is invasive and not without its own inherent risks (Hoeper et al 2006). For these reasons, development of a noninvasive alternative to RHC for diagnosis of PH is paramount.

Noninvasive diagnosis of PH and prediction of response to vasodilator challenge is clinically needed.

Several noninvasive methods for diagnosis of PH have been propounded, the most common being Doppler echocardiography. While routinely used to estimate pulmonary arterial pressure, Doppler measurement of tricuspid regurgitation jet peak velocity has inherent limitations: (i) the reliance on the visualization of the tricuspid regurgitant jet which is not always detectable, (ii) the fact that peak velocity of the jet may be difficult to measure in the presence of severe tricuspid regurgitation, and (iii) the need for adequate acoustic windows (Hinderliter et al 2003; Hachulla et al 2005). Furthermore, as recently emphasized in the ERS/ESC guideline (Galie et al 2009), estimation of mPAP or PVR must be an integral part of a complete cardiac echocardiographic examination.

It has long been recognized that systolic flattening and abnormal motion of the inter-ventricular septum (IVS), from either echocardiography (King et al 1983; Reisner et al 1994; Ricciardi et al 1999) or cine CMR images (Roeleveld et al 2005; Dellegrottaglie et al 2007; Alunni et al 2010), are signs of increased pulmonary arterial pressures. However, these studies are either qualitative or limited to 2D assessment, relying for analysis on subjective selection of the imaging plane and cardiac cycle phase. In the last 10 years, despite advances in biomedical engineering and computational approaches, no rigorous studies have been undertaken to study the relationship between quantitative 3D IVS shape and PH.

It is well documented that RV dysfunction and the 6-min walk test (6MWT) are associated with increased risk of mortality in PH (van Wolfersen 2007). Study team has recently developed a new method for assessment of RV function in terms of area strain, integrating radial, circumferential and longitudinal deformation (Zhong et al 2012). Therefore, we will also investigate the relationship between RV area strain and exercise capacity in PH.

Being tested
6MWT, Cardiovascular Magnetic Resonance Imaging (CMRI)
Keywords
Pulmonary Hypertension, MRI
Medical subject headings
Hypertension, Pulmonary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 6MWTOther

    Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.

  • Cardiovascular Magnetic Resonance Imaging (CMRI)Other

    MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.

Study groups in NCT02790918
Study groupRoleWhat they receive
Diagnosed Pulmonary HypertensionPatients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
Receives: Other: 6MWT; Other: Cardiovascular Magnetic Resonance Imaging (CMRI)
Healthy VolunteerHealthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
Receives: Other: 6MWT; Other: Cardiovascular Magnetic Resonance Imaging (CMRI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. First occurrence of cardiovascular event.

    Measured: 1-Year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jun 2016 (estimated)
  2. Study startMay 2013
  3. Primary completionOct 2019
  4. Study completionOct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02790918
Sponsor's protocol ID
2013/290/C
Status last verified
Aug 2020
First submitted
30 May 2016
Last updated
4 Aug 2020
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Leng S, Dong Y, Wu Y, Zhao X, Ruan W, Zhang G, Allen JC, Koh AS, Tan RS, Yip JW, Tan JL, Chen Y, Zhong L. Impaired Cardiovascular Magnetic Resonance-Derived Rapid Semiautomated Right Atrial Longitudinal Strain Is Associated With Decompensated Hemodynamics in Pulmonary Arterial Hypertension. Circ Cardiovasc Imaging. 2019 May;12(5):e008582. doi: 10.1161/CIRCIMAGING.118.008582.

    PubMed 31088152

Questions about this trial

What is this clinical trial studying?

An observational study of Pulmonary Hypertension, run by National Heart Centre Singapore at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First occurrence of cardiovascular event. (time frame: 1-Year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02790918, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in